News - POCTRN
binx health Receives FDA CLIA Waiver for Chlamydia and Gonorrhea Test, Expanding Critical Access to Single-Visit Diagnoses
University Lab Partners Selected by CIMIT to Partner in their Project to Support the NIH RADx Initiative
The Forsyth Institute Serving as a Critical Resource for COVID-19 Saliva Diagnostic Test Development
Webinar: Understanding the FDA - Accelerating the Pathway to Approval for Point-of-Care Technologies
Use of a Rapid Diagnostic for Chlamydia Trachomatis and Neisseria Gonorrhoeae for Women in the Emergency Department Can Improve Clinical Management
RADx: Rapid Acceleration of Diagnostics
In response to the COVID-19 pandemic, the Rapid Acceleration of Diagnostics (RADxsm) initiative was formed to accelerate the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improvements to clinical laboratory tests, that can directly detect SARS-CoV-2, the virus that causes COVID-19.